BOSTON, Mass. — Odyssey Therapeutics Inc., a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases, has appointed H. Martin Seidel, Ph.D., to its Scientific Advisory Board.
Dr. Seidel brings decades of experience in drug discovery and development across both biotechnology and large pharmaceutical companies. He currently serves as Chief Executive Officer of IFM Therapeutics, where he has overseen the advancement of multiple discovery and development programs as well as three successful portfolio company exits.
Prior to joining IFM Therapeutics, Dr. Seidel spent more than a decade at the Novartis Institutes for Biomedical Research, where he held several senior leadership positions. His roles included Head of the Genomics Institute of the Novartis Research Foundation and Global Head of Business Development and Licensing. In those positions, he led scientific collaborations, strategic transactions, and efforts to advance discovery programs into clinical development.
“Martin brings exceptional depth of experience in drug discovery, translational science and portfolio strategy,” said Gary D. Glick, Ph.D., Founder and CEO of Odyssey Therapeutics. “Martin and I have worked closely together in the past, as have other members of our scientific leadership team, including Dennis Dean, Ph.D., Luigi Franchi, M.D., Ph.D., Tony Opipari, M.D., Ph.D., and Bill Roush, Ph.D. That shared experience gives us deep confidence in his scientific judgment and his ability to help guide our scientific direction. His perspective, shaped by decades of advancing programs across diverse scientific platforms, will be highly valuable as we continue to identify and advance targets toward the clinic. We are pleased to welcome him to the Scientific Advisory Board at this important stage for the company.”
Odyssey Therapeutics is focused on developing precision medicines designed to target the underlying biological mechanisms of autoimmune and inflammatory diseases.
“Odyssey is working in an area of biology that is particularly ripe for drug discovery, and the breadth of scientific capabilities the team has assembled is unusual in today’s biotech landscape. Having worked previously with members of the Odyssey scientific leadership team, I have developed a strong appreciation for their scientific rigor and ambition. My work has long focused on applying cutting-edge science to drug discovery, and I look forward to contributing my experience across target selection and translation as Odyssey advances its programs toward the clinic,” said Dr. Seidel.
The company said Dr. Seidel joins a Scientific Advisory Board composed of experts in immunology, inflammation biology, and therapeutic development who provide strategic guidance as Odyssey advances its lead programs toward clinical evaluation and continues to expand its research pipeline.
